India may soon see its first approved dengue vaccine as the SEC under CDSCO has recommended import permission for Takeda’s Qdenga (TDV) for ages 4–60. Backed by global approvals and Indian trials, the vaccine promises safer, broader protection. With Hyderabad-based Biological E set to manufacture millions of doses, this marks a major public health milestone.